Schrodinger raises 2026 ACV and drug discovery revenue guidance in Q3 results

Schrödinger, Inc. reported third quarter 2026 results on November 4, 2026, alongside several pipeline updates. In September, Takeda announced that the FDA accepted its New Drug Application under Priority Review for zasocitinib (TAK-279), a TYK2 inhibitor for moderate-to-severe plaque psoriasis that was co-invented by Schrödinger and Nimbus and later acquired by Takeda.¹

In September, Schrödinger also received a milestone payment from Structure Therapeutics, a company it co-founded, tied to Structure's Phase 1/2a study of ACCG-2671, an oral small molecule amylin candidate for obesity and metabolic diseases.¹ Separately, the company said updated Phase 1 data for SGR-1505 will be presented in an oral session at the ASH Annual Meeting, scheduled for December 12-15, 2026, in New Orleans.¹

In a Regulation FD disclosure filed the same day, Schrödinger said it was correcting information in its ASH abstract on SGR-1505. The abstract had stated the company has an ongoing combination study of the drug in patients with relapsed or refractory B cell malignancies, but the company said it has not actually initiated a combination study under its FDA-cleared protocol, and as previously disclosed, is exploring strategic opportunities to continue developing SGR-1505.¹

On financial guidance, Schrödinger raised its full-year 2026 ACV outlook to a range of $222 million to $232 million, representing 12-17% growth over 2025, up from a prior forecast of $218 million to $228 million, or 10-15% growth.¹ It also raised its drug discovery revenue outlook to a range of $75 million to $85 million, up from a prior range of $65 million to $75 million.¹

For the quarter, ACV was $44.7 million, a 17% increase, and $214 million on a trailing four-quarter basis.¹ Drug discovery revenue rose to $24.2 million from $13.0 million a year earlier, driven largely by recognition of a milestone payment from Structure Therapeutics.¹ The company reported cash, cash equivalents, restricted cash and marketable securities of $373 million as of the quarter's end.¹